AVTX Annual Cash & Cash Equivalents
$7.42 M
-$5.76 M-43.71%
31 December 2023
Summary:
As of January 23, 2025, AVTX annual cash & cash equivalents is $7.42 million, with the most recent change of -$5.76 million (-43.71%) on December 31, 2023. During the last 3 years, it has fallen by -$11.50 million (-60.81%). AVTX annual cash & cash equivalents is now -86.42% below its all-time high of $54.59 million, reached on December 31, 2021.AVTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVTX Quarterly Cash And Cash Equivalents
$81.86 M
-$11.57 M-12.38%
30 September 2024
Summary:
As of January 23, 2025, AVTX quarterly cash and cash equivalents is $81.86 million, with the most recent change of -$11.57 million (-12.38%) on September 30, 2024. Over the past year, it has dropped by -$11.57 million (-12.38%). AVTX quarterly cash and cash equivalents is now -25.70% below its all-time high of $110.18 million, reached on March 31, 2024.AVTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVTX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -43.7% | -12.4% |
| 3 y3 years | -60.8% | +521.5% |
| 5 y5 years | -30.4% | +1459.0% |
AVTX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -86.4% | at low | -25.7% | +1197.9% |
| 5 y | 5-year | -86.4% | +105.4% | -25.7% | +2167.9% |
| alltime | all time | -86.4% | +199.9% | -25.7% | +3655.3% |
Avalo Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $81.86 M(-12.4%) |
| June 2024 | - | $93.43 M(-15.2%) |
| Mar 2024 | - | $110.18 M(+1385.9%) |
| Dec 2023 | $7.42 M(-43.7%) | $7.42 M(-27.2%) |
| Sept 2023 | - | $10.18 M(+61.4%) |
| June 2023 | - | $6.31 M(-62.2%) |
| Mar 2023 | - | $16.69 M(+26.7%) |
| Dec 2022 | $13.17 M(-75.9%) | $13.17 M(-22.3%) |
| Sept 2022 | - | $16.94 M(+50.6%) |
| June 2022 | - | $11.25 M(-70.8%) |
| Mar 2022 | - | $38.47 M(-29.5%) |
| Dec 2021 | $54.59 M(+188.5%) | $54.59 M(-23.7%) |
| Sept 2021 | - | $71.51 M(+76.8%) |
| June 2021 | - | $40.44 M(+5.6%) |
| Mar 2021 | - | $38.29 M(+102.4%) |
| Dec 2020 | $18.92 M(+424.2%) | $18.92 M(-43.3%) |
| Sept 2020 | - | $33.39 M(-26.4%) |
| June 2020 | - | $45.39 M(+702.0%) |
| Mar 2020 | - | $5.66 M(+56.8%) |
| Dec 2019 | $3.61 M | $3.61 M(-31.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2019 | - | $5.25 M(-44.1%) |
| June 2019 | - | $9.39 M(-41.8%) |
| Mar 2019 | - | $16.12 M(+51.4%) |
| Dec 2018 | $10.65 M(+330.6%) | $10.65 M(+55.7%) |
| Sept 2018 | - | $6.84 M(+213.7%) |
| June 2018 | - | $2.18 M(-13.6%) |
| Mar 2018 | - | $2.52 M(+2.1%) |
| Dec 2017 | $2.47 M(-51.8%) | $2.47 M(-89.7%) |
| Sept 2017 | - | $23.96 M(+338.7%) |
| June 2017 | - | $5.46 M(+81.9%) |
| Mar 2017 | - | $3.00 M(-41.5%) |
| Dec 2016 | $5.13 M(-75.8%) | $5.13 M(-41.8%) |
| Sept 2016 | - | $8.82 M(-25.8%) |
| June 2016 | - | $11.88 M(-28.4%) |
| Mar 2016 | - | $16.60 M(-21.5%) |
| Dec 2015 | $21.16 M(+80.2%) | $21.16 M(+539.7%) |
| Sept 2015 | - | $3.31 M(-46.1%) |
| June 2015 | - | $6.14 M(-28.6%) |
| Mar 2015 | - | $8.60 M(-26.8%) |
| Dec 2014 | $11.74 M(+243.2%) | $11.74 M |
| Dec 2013 | $3.42 M | - |
FAQ
- What is Avalo Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Avalo Therapeutics?
- What is Avalo Therapeutics annual cash & cash equivalents year-on-year change?
- What is Avalo Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Avalo Therapeutics?
- What is Avalo Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Avalo Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of AVTX is $7.42 M
What is the all time high annual cash & cash equivalents for Avalo Therapeutics?
Avalo Therapeutics all-time high annual cash & cash equivalents is $54.59 M
What is Avalo Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, AVTX annual cash & cash equivalents has changed by -$5.76 M (-43.71%)
What is Avalo Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of AVTX is $81.86 M
What is the all time high quarterly cash and cash equivalents for Avalo Therapeutics?
Avalo Therapeutics all-time high quarterly cash and cash equivalents is $110.18 M
What is Avalo Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, AVTX quarterly cash and cash equivalents has changed by -$11.57 M (-12.38%)